CTOs on the Move

Cybrexa

www.cybrexa.com

 
Cybrexa is a clinical-stage oncology biotechnology company developing novel antigen-independent peptide drug conjugates (ADCs) aimed at combatting a range of cancer types, including ovarian, breast and non-small cell lung cancer. With the potential to disrupt the standard of care, the Cybrexa alphalex™ technology is a novel antigen-independent peptide drug conjugate (PDC) platform that enables targeted delivery of highly potent anticancer treatments and aims to revolutionize the standard of care in oncology. The platform consists of a pHLIP® peptide, linker, and small molecule anti-cancer agent. pHLIP® peptides are a family of pH-Low Insertion Peptides that target acidic cell surfaces. pHLIP® was developed at ...
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.cybrexa.com
  • 5 Science Park 395 Winchester Avenue
    New Haven, CT USA 06511
  • Phone: 860.717.2731

Executives

Name Title Contact Details
Jaya Gautam
 Senior Vice President of Technical Operations Profile

Funding

Cybrexa raised $13.4M on 06/21/2019
Cybrexa raised $25M on 03/10/2021

Similar Companies

Zymeworks

Zymeworks (NASDAQ:ZYME) is a clinical-stage biopharmaceutical company dedicated to the development of next-generation multifunctional biotherapeutics. Zymeworks` suite of therapeutic platforms and its fully integrated drug development engine enable precise engineering of highly differentiated product candidates. Zymeworks` lead clinical candidate, zanidatamab, is a novel Azymetric™ HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. Zymeworks` second product candidate, Zanidatamab Zovodotin (ZW49), is a bispecific antibody-drug conjugate currently in Phase 1 clinical development and combines the unique design and antibody framework of zanidatamab with Zymeworks` proprietary ZymeLink™ linker-cytotoxin. Zymeworks is also advancing a deep preclinical pipeline in oncology (including immuno-oncology agents) and other therapeutic areas. In addition, its therapeutic platforms are being leveraged through strategic partnerships with nine biopharmaceutical companies.

EMD Biosciences

EMD Biosciences, Inc. is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Adjuvance Technologies

Helping protect life through fundamental breakthroughs in vaccine adjuvant design and manufacturing.

Taueret Laboratories

Taueret Laboratories is a Salt Lake City, UT-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Bavarian Nordic

Bavarian Nordic is a fully integrated biotechnology company focused on the development, manufacture and commercialization of life-saving vaccines.